Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). It is a tyrosine kinase inhibitor (TKI) designed to target the BCR-ABL protein, including mutations that are resistant to other TKIs. Ponatinib is particularly effective against the T315I mutation, which is known for its resistance to many other treatments.
Parent: Ponatinib
Impurities in Ponatinib can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Yes, ponatinib is considered a targeted chemotherapy drug. Unlike traditional chemotherapy, which kills rapidly dividing cells indiscriminately, ponatinib selectively inhibits specific tyrosine kinases involved in the growth of cancer cells.
Ponatinib was temporarily withdrawn from the market in 2013 due to concerns about serious cardiovascular risks, including blood clots and stroke. After further evaluation and label revisions to manage these risks, it was reintroduced with a restricted distribution program.
Ponatinib belongs to the class of tyrosine kinase inhibitors (TKIs), specifically targeting the BCR-ABL tyrosine kinase and other kinases involved in cancer cell proliferation.
Ponatinib has shown a high success rate, particularly for patients with resistant forms of CML and the T315I mutation. Clinical trials reported major cytogenetic response (MCyR) rates of around 40-50% for heavily pretreated patients. However, the effectiveness varies based on the patient’s condition and mutation profile.
